Ironwood Pharmaceuticals, Inc. (IRWD)

NASDAQ: IRWD · IEX Real-Time Price · USD
11.70
-0.17 (-1.43%)
Aug 8, 2022 4:00 PM EDT - Market closed
-1.43%
Market Cap 1.80B
Revenue (ttm) 415.64M
Net Income (ttm) 173.10M
Shares Out 153.84M
EPS (ttm) 3.28
PE Ratio 3.57
Forward PE 12.33
Dividend n/a
Ex-Dividend Date n/a
Volume 2,652,914
Open 11.95
Previous Close 11.87
Day's Range 11.52 - 11.97
52-Week Range 10.13 - 14.27
Beta 1.00
Analysts Buy
Price Target 12.58 (+7.5%)
Earnings Date Aug 4, 2022

About IRWD

Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Mexico, as well as under the CONSTELLA name in the Canada and European Union. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain co... [Read more...]

Industry Biotechnology
IPO Date Feb 3, 2010
CEO Mark Mallon
Employees 219
Stock Exchange NASDAQ
Ticker Symbol IRWD
Full Company Profile

Financial Performance

In 2021, IRWD's revenue was $413.75 million, an increase of 6.22% compared to the previous year's $389.52 million. Earnings were $528.45 million, an increase of 397.71%.

Financial Statements

Analyst Forecast

According to 10 analysts, the average rating for IRWD stock is "Buy." The 12-month stock price forecast is 12.58, which is an increase of 7.52% from the latest price.

Price Target
$12.58
(7.52% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Ironwood (IRWD) Q2 Earnings Miss, Keeps 2022 Sales Guidance

Ironwood (IRWD) miss earnings and revenue estimates in the second quarter. Stock declines.

Ironwood Pharmaceuticals (IRWD) Misses Q2 Earnings and Revenue Estimates

Ironwood (IRWD) delivered earnings and revenue surprises of -32.26% and 2.19%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Ironwood Pharmaceuticals Reports Second Quarter 2022 Results; Maintains Full Year Guidance Due to Continued Strength ...

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, today reported its second quarter 2022 results and recent business performance. “We made progress...

Ironwood Pharmaceuticals to Host Second Quarter 2022 Investor Update Call

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced it will host its second quarter 2022 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thurs...

4 Graham-Style Stocks to Consider

To increase your chances of discovering value opportunities, you may want to look for stocks whose Graham blended multipliers are below 22.5. Created by Benjamin Graham, the father of value investing, t...

Other symbols: MROSAN

Ironwood Presents New Data Demonstrating Potential of IW-3300 for Visceral Pain at Digestive Disease Week® (DDW) 2022

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, presented new findings during the 2022 Digestive Disease Week® (DDW) meeting that suggest colonic...

Ironwood Pharmaceuticals to Present New IW-3300 and Linaclotide Data at Digestive Disease Week® 2022

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, today announced that the company and its collaborators will present eight studies, including two ...

Ironwood (IRWD) Q1 Earnings Miss, Linzess Growth Continues

Ironwood (IRWD) witnesses strong year-over-year sales growth on continued demand for Linzess. Its first-quarter earnings miss estimates.

Ironwood Pharmaceuticals (IRWD) Q1 Earnings Miss Estimates

Ironwood (IRWD) delivered earnings and revenue surprises of -22.22% and 2.13%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Ironwood Pharmaceuticals Reports First Quarter 2022 Results; Maintains Full Year 2022 Financial Guidance

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, today reported its first quarter 2022 results and recent business performance. “Continuing the gr...

Ironwood Pharmaceuticals (IRWD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Ironwood (IRWD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Ironwood Pharmaceuticals to Host First Quarter 2022 Investor Update Call

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced it will host its first quarter 2022 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursd...

Ironwood Pharmaceuticals (IRWD) is a Top-Ranked Momentum Stock: Should You Buy?

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Ironwood Pharmaceuticals to Present at Upcoming Investor Conferences

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, today announced that management will be presenting at the following investor conferences: Cowen 4...

Ironwood (IRWD) Q4 Earnings Miss, Linzess Volume Grows

Ironwood (IRWD) witnesses flat year-over-year sales growth. Its fourth-quarter earnings miss estimates.

Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Results; LINZESS® (linaclotide) Achieves Blockbust...

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, today reported its fourth quarter and full year 2021 results. “The tremendous progress we made ag...

Medical Stocks' Q4 Earnings on Feb 17: RGEN, IRWD & More

Let us take a look at four biotech or drug companies - RGEN, IRWD, EXEL and LGND - due to release their quarterly results on Feb 16.

Other symbols: EXELLGNDRGEN

Is Ironwood Pharmaceuticals (IRWD) a Suitable Stock for Value Investors?

Is Ironwood Pharmaceuticals (IRWD) a great pick from the value investor's perspective right now? Read on to know more.

Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2021 Investor Update Call

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced it will host its fourth quarter and full year 2021 investor update conference call and webcast at 8:30 a.m. Eastern...

Ironwood Pharmaceuticals Provides Update on FY 2021 Financial Guidance and Announces FY 2022 Financial Guidance

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, today provided updated financial guidance for full year 2021 and announced financial guidance for...

Ironwood Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a GI-focused healthcare company, today announced that Tom McCourt, CEO, will present at the 40th Annual J.P. Morgan Healthcare Con...

Robot Portfolio: Value in the Extreme

Investors are keenly aware that growth stocks have beaten value stocks five years in a row. So what am I going to recommend today?

Ironwood Pharmaceuticals Appoints Sravan K. Emany as Chief Financial Officer

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a GI-focused healthcare company, today announced the appointment of Sravan K. Emany as senior vice president, chief financial offi...

Ironwood (IRWD) Q3 Earnings Top, Sales Hurt by Lower Price

Ironwood (IRWD) witnesses flat year-over-year sales as growth in demand for Linzess gets partially offset by lower net price of the drug. The company maintains revenue guidance.

Ironwood Pharmaceuticals (IRWD) Q3 Earnings Surpass Estimates

Ironwood (IRWD) delivered earnings and revenue surprises of 6.45% and -1.32%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?